Login to Your Account



Alvimopan Phase III Results Provide Adolor With Boost

By Kim Coghill


Thursday, April 3, 2003
Adolor Corp.'s stock hit a springboard, bouncing up about 31.3 percent Wednesday after the company released positive data from its first Phase III study of lead product alvimopan in the management of postoperative ileus.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription